Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycles

Gynecological Endocrinology

Volumn 21, Issue 4, 2005, Pages 218-222

  Orvieto, Raoul ^a,b,d   Yulzari Roll, Vered ^a,b   La Marca, Antonio ^c   Ashkenazi, Jacob ^a,b   Fisch, Benjamin ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d BARZILAI MEDICAL CENTER   (Israel)

Author keywords

Androgens; Aromatase activity; Controlled ovarian hyperstimulation; Dehydroepiandrosterone sulfate; In vitro fertilization; Testosterone

Indexed keywords

ANDROSTENEDIONE; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN; HYDROXYPROGESTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; AMPOULE; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; OBSERVATION; OOCYTE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; UNIVERSITY HOSPITAL;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; ANDROGENS; ANDROSTENEDIONE; CHORIONIC GONADOTROPIN; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVULATION INDUCTION; PROGESTERONE; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 28844496712     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500279691     Document Type: Article

References (21)

1. Ben Shlomo I, Geslevich J, Shalev E. Can we abandon routine evaluation of serum estradiol levels during controlled ovarian hyperstimulation for assisted reproduction? Fertil Steril 2001;76:300-303.
2. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 2003;18:665-667.
3. Cedars MI, Surey E, Hamilton F, Lapolt P, Meldrum DR. Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval. Fertil Steril 1990;53:627-631.
4. Tadmor OP, Kleinman Y, Barr I, Gal M, Brooks BA, Diamant YZ. Side effects of ovarian hyperstimulation: hormonal and lipid profile changes. Int J Fertil Menopausal Stud 1994;39:105-110.
5. Fanchin R, de Ziegler D, Castracane VD, Taieb J, Olivennes F, Frydman R. Physiopathology of premature progesterone elevation. Fertil Steril 1995;64:796-801.
6. Fanchin R, Righini C, Olivennes F, Taieb J, de Ziegler D, Frydman R. Premature plasma progesterone and androgen elevation are not prevented by adrenal suppression in in vitro fertilization. Fertil Steril 1997;67:115-119.
7. Martin KA, Hornstein MD, Taylor AE, Hall JE, Barbieri RL. Exogenous gonadotropin stimulation is associated with increases in serum androgen levels in in-vitro fertilization-embryo transfer cycles. Fertil Steril 1997;68:1011-1016.
8. Tanbo T, Dale PO, Abyholm T. Recombinant follicle-stimulating hormone stimulates ovarian androgen synthesis in down-regulated ovulatory women. Gynecol Endocrinol 2001;15:407-412.
9. Speroff L, Glass RB, Kase NG, editors. Clinical gynecologic endocrinology and infertility. 6th ed. Maryland: Lippincott, Williams & Wilkins; 1999.
10. Judd HL, Lucas WE, Yen SSC. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118:793-798.
11. Slater CC, Chang L, Stanczyk FZ, Paulson RJ. Altered balance between the 5α-reductase and aromatase pathways of androgen metabolism during controlled ovarian hyperstimulation with human menopsausal gonadotropins. J Assist Reprod Genet 2001;18:527-533.
12. Fanchin R, de Ziegler D, Taieb J, Olivennes F, Castracane D, Frydman R. Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation. Fertil Steril 2000;73:275-279.
13. Casper RF, Erickson GF, Rebar RW, Yen SSC. The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cells. Fertil Steril 1982;37:406-409.
14. Casper RF, Erickson GF, Yen SS. Studies on the effect of gonadotropin-releasing hormone and its agonist on human luteal steroidogenesis in vitro. Fertil Steril 1984;42:39-43.
15. Cumming DC, Wall SR. Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. J Clin Endocrinol Metab 1985;61:873-876.
16. Andersen CY, Ziebe S. Serum levels of free androstenedione, testosterone and oestradiol are lower in the follicular phase of conceptional than of non-conceptional cycles after ovarian stimulation with a gonadotrophin-releasing hormone agonist protocol. Hum Reprod 1992;7:1365-1370.
17. Check JH, Nazari A, Dietterich C. Comparison of androgen levels in conception vs. non-conception cycles following controlled ovarian stimulation using the luteal phase gonadotropin-releasing hormone agonist protocol. Gynecol Endocrinol 1995;9:209-214.
18. Edwards RG, Fishel SB, Cohen J, Fehilly CB, Purdy JM, Slater JM, Steptoe PC, Webster JM. Factors influencing the success of in-vitro fertilization for alleviating human infertility. J In Vitro Fert Embryo Transf 1984;1:3-23.
19. Sharma V, Riddle A, Mason BA, Pampiglione J, Campbell S. An analysis of factors influencing the establishment of a clinical pregnancy in an ultrasound-based ambulatory in vitro fertilization programme. Fertil Steril 1988;49:468-478.
20. Hoff JD, Quigley ME, Yen SSC. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab 1983;57:792-796.
21. Castracane VD, Goldzieher JW. Plasma androgens during early pregnancy in the baboon (Papio cynocephalus). Fertil Steril 1983;39:553-559.